Digestive and Liver Disease
Volume 42, Issue 8 , Pages 529-536 , August 2010

A review of mast cells and liver disease: What have we learned?

  • Heather Francis

      Affiliations

    • Department of Internal Medicine, College of Medicine, Texas A&M Health Science Center, Temple, TX, United States
    • Department of Research and Education, Scott & White Hospital, College of Medicine, Texas A&M Health Science Center, Temple, TX, United States
    • Systems Biology and Translational Medicine, College of Medicine, Texas A&M Health Science Center, Temple, TX, United States
    • Corresponding Author InformationCorresponding author at: Texas A&M University COM/Scott & White Hospital, 702 SW H.K. Dodgen Loop, MRB, Temple, TX, United States. Tel.: +1 254 742 7055.
    • ,
  • Cynthia J. Meininger

      Affiliations

    • Systems Biology and Translational Medicine, College of Medicine, Texas A&M Health Science Center, Temple, TX, United States

Received 21 December 2009 ,Accepted 25 February 2010.

References 

  1. Beaven MA. Our perception of the mast cell from paul ehrlich to now. Eur J Immunol. 2009;39:11–25
  2. Vyas H, Krishnaswamy G. Paul ehrlich's “Mastzellen”—from aniline dyes to DNA chip arrays: a historical review of developments in mast cell research. Methods Mol Biol. 2006;315:3–11
  3. Rao KN, Brown MA. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann NY Acad Sci. 2008;1143:83–104
  4. Piro A, Tagarelli A, Tagarelli G, et al. Paul Ehrlich: the Nobel Prize in physiology or medicine 1908. Int Rev Immunol. 2008;27:1–17
  5. Ishizaka T, Mitsui H, Yanagida M, et al. Development of human mast cells from their progenitors. Curr Opin Immunol. 1993;5:937–943
  6. Yong LC. The mast cell: origin, morphology, distribution, and function. Exp Toxicol Pathol. 1997;49:409–424
  7. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol. 1993;142:965–974
  8. Shiohara M, Koike K. Regulation of mast cell development. Chem Immunol Allergy. 2005;87:1–21
  9. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9:1215–1223
  10. Bachelet I, Levi-Schaffer F, Mekori YA. Mast cells: not only in allergy. Immunol Allergy Clin N Am. 2006;26:407–425
  11. Weber S, Babina M, Feller G, et al. Human leukaemic (hmc-1) and normal skin mast cells express beta 2-integrins: characterization of beta 2-integrins and icam-1 on hmc-1 cells. Scand J Immunol. 1997;45:471–481
  12. Stahl JL, Cook EB, Graziano FM, et al. Human conjunctival mast cells: expression of fc epsilonri, c-kit, icam-1, and ige. Arch Ophthalmol. 1999;117:493–497
  13. Chen W, Beck I, Schober W, et al. Human mast cells express androgen receptors but treatment with testosterone exerts no influence on ige-independent mast cell degranulation elicited by neuromuscular blocking agents. Exp Dermatol. 2009;
  14. Wareham K, Vial C, Wykes RC, et al. Functional evidence for the expression of p2×1, p2×4 and p2×7 receptors in human lung mast cells. Br J Pharmacol. 2009;157:1215–1224
  15. Meijers JM . Work conflict and mental disorders. Ned Tijdschr Geneeskd. 1991;135:2097–2098
  16. Detoraki A, Staiano RI, Granata F, et al. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol. 2009;123:1142–11491149 e1141–1145
  17. Abdel-Majid RM, Marshall JS. Prostaglandin e2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol. 2004;172:1227–1236
  18. Quist RG, Ton-Nu HT, Lillienau J, et al. Activation of mast cells by bile acids. Gastroenterology. 1991;101:446–456
  19. Schrader JW, Schallhorn A, Grill B, et al. Activation of small gtpases of the ras and rho family by growth factors active on mast cells. Mol Immunol. 2002;38:1181–1186
  20. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (crh) receptors and crh leads to selective secretion of vascular endothelial growth factor. J Immunol. 2005;174:7665–7675
  21. Cao J, Cetrulo CL, Theoharides TC. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the camp/protein kinase a/p38 mitogen-activated protein kinase pathway. Mol Pharmacol. 2006;69:998–1006
  22. Kinet JP. The high-affinity ige receptor (fc epsilon ri): from physiology to pathology. Annu Rev Immunol. 1999;17:931–972
  23. Bradding P. Human lung mast cell heterogeneity. Thorax. 2009;64:278–280
  24. Agafonov VE, Mitereva DE, Makarova OV, et al. Morphofunctional characterization of mast cells of the skin and the mucous membrane of airways in specific hyposensitization carried out on an experimental model. Zh Mikrobiol Epidemiol Immunobiol. 2006;61–65
  25. Weidner N, Austen KF. Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites. J Invest Dermatol. 1991;96:26S–30S[discussion 30S–31S, 60S–65S]
  26. Sperr WR, Bankl HC, Mundigler G, et al. The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood. 1994;84:3876–3884
  27. Patella V, Marino I, Lamparter B, et al. Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. J Immunol. 1995;154:2855–2865
  28. Meindl S, Schmidt U, Vaculik C, et al. Characterization, isolation, and differentiation of murine skin cells expressing hematopoietic stem cell markers. J Leukoc Biol. 2006;80:816–826
  29. Wallon C, Soderholm JD. Corticotropin-releasing hormone and mast cells in the regulation of mucosal barrier function in the human colon. Ann NY Acad Sci. 2009;1165:206–210
  30. Bischoff SC. Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol. 2009;31:185–205
  31. Traver E, Torres R, de Mora F, et al. Mucosal mast cells mediate motor response induced by chronic oral exposure to ovalbumin in the rat gastrointestinal tract. Neurogastroenterol Motil. 2010;22:e34–e43
  32. Ehara T, Shigematsu H. Mast cells in the kidney. Nephrology (Carlton). 2003;8:130–138
  33. Blank U, Essig M, Scandiuzzi L, et al. Mast cells and inflammatory kidney disease. Immunol Rev. 2007;217:79–95
  34. Chan A, Cooley MA, Collins AM. Mast cells in the rat liver are phenotypically heterogeneous and exhibit features of immaturity. Immunol Cell Biol. 2001;79:35–40
  35. Irani AA, Schechter NM, Craig SS, et al. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA. 1986;83:4464–4468
  36. Bradding P, Okayama Y, Howarth PH, et al. Heterogeneity of human mast cells based on cytokine content. J Immunol. 1995;155:297–307
  37. Patella V, de Crescenzo G, Ciccarelli A, et al. Human heart mast cells: a definitive case of mast cell heterogeneity. Int Arch Allergy Immunol. 1995;106:386–393
  38. Zweifel M, Breu K, Matozan K, et al. Restoration of hepatic mast cells and expression of a different mast cell protease phenotype in regenerating rat liver after 70%-hepatectomy. Immunol Cell Biol. 2005;83:587–595
  39. Welle M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol. 1997;61:233–245
  40. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in w/wv mice and their increase by bone marrow transplantation. Blood. 1978;52:447–452
  41. Kitamura Y, Shimada M, Hatanaka K, et al. Development of mast cells from grafted bone marrow cells in irradiated mice. Nature. 1977;268:442–443
  42. Hayashi C, Sonoda T, Nakano T, et al. Mast-cell precursors in the skin of mouse embryos and their deficiency in embryos of sl/sld genotype. Dev Biol. 1985;109:234–241
  43. Wershil BK. Ix. Mast cell-deficient mice and intestinal biology. Am J Physiol Gastrointest Liver Physiol. 2000;278:G343–G348
  44. Brannan CI, Lyman SD, Williams DE, et al. Steel-dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains. Proc Natl Acad Sci USA. 1991;88:4671–4674
  45. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol. 1994;55:1–96
  46. Nocka K, Tan JC, Chiu E, et al. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, wv, w41 and w. EMBO J. 1990;9:1805–1813
  47. Tei H, Kasugai T, Tsujimura T, et al. Characterization of cultured mast cells derived from ws/ws mast cell-deficient rats with a small deletion at tyrosine kinase domain of c-kit. Blood. 1994;83:916–925
  48. Tsujimura T, Hirota S, Nomura S, et al. Characterization of ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene. Blood. 1991;78:1942–1946
  49. Arizono N, Kasugai T, Yamada M, et al. Infection of nippostrongylus brasiliensis induces development of mucosal-type but not connective tissue-type mast cells in genetically mast cell-deficient ws/ws rats. Blood. 1993;81:2572–2578
  50. Niwa Y, Kasugai T, Ohno K, et al. Anemia and mast cell depletion in mutant rats that are homozygous at “White spotting (ws)” locus. Blood. 1991;78:1936–1941
  51. Kennedy RH, Hauer-Jensen M, Joseph J. Cardiac function in hearts isolated from a rat model deficient in mast cells. Am J Physiol Heart Circ Physiol. 2005;288:H632–H637
  52. Miyazawa S, Hotta O, Doi N, et al. Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. Kidney Int. 2004;65:2228–2237
  53. Shibamoto T, Shimo T, Cui S, et al. The roles of mast cells and Kupffer cells in rat systemic anaphylaxis. Am J Physiol Regul Integr Comp Physiol. 2007;293:R2202–R2209
  54. Farrell DJ, Hines JE, Walls AF, et al. Intrahepatic mast cells in chronic liver diseases. Hepatology. 1995;22:1175–1181
  55. O’Keeffe C, Baird AW, Nolan N, et al. Mast cell hyperplasia in chronic rejection after liver transplantation. Liver Transpl. 2002;8:50–57
  56. Franceschini B, Ceva-Grimaldi G, Russo C, et al. The complex functions of mast cells in chronic human liver diseases. Dig Dis Sci. 2006;51:2248–2256
  57. Koda W, Harada K, Tsuneyama K, et al. Evidence of the participation of peribiliary mast cells in regulation of the peribiliary vascular plexus along the intrahepatic biliary tree. Lab Invest. 2000;80:1007–1017
  58. Bardadin KA, Scheuer PJ. Mast cells in acute hepatitis. J Pathol. 1986;149:315–325
  59. Yamashiro M, Kouda W, Kono N, et al. Distribution of intrahepatic mast cells in various hepatobiliary disorders. An immunohistochemical study. Virchows Arch. 1998;433:471–479
  60. Michels NA. Newer anatomy of the liver and its variant blood supply and collateral circulation. Am J Surg. 1966;112:337–347
  61. Rappaport AM. Hepatic blood flow: morphologic aspects and physiologic regulation. Int Rev Physiol. 1980;21:1–63
  62. Vidal-Vanaclocha F, Barbera-Guillem E. Fenestration patterns in endothelial cells of rat liver sinusoids. J Ultrastruct Res. 1985;90:115–123
  63. Esteller A. Physiology of bile secretion. World J Gastroenterol. 2008;14:5641–5649
  64. Dooley S, Weng H, Mertens PR. Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma. Dig Dis. 2009;27:93–101
  65. Xia X, Francis H, Glaser S, et al. Bile acid interactions with cholangiocytes. World J Gastroenterol. 2006;12:3553–3563
  66. Alpini G, Prall RT, LaRusso NF. The pathobiology of biliary epithelia. In:  Arias IM,  Boyer JL,  Chisari FV,  Fausto N,  Jakoby W,  Schachter D,  Shafritz DA editor. The Liver, Biology & Pathobiology. 4th ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 421–435
  67. Birnbaum A, Suchy FJ. The intrahepatic cholangiopathies. Semin Liver Dis. 1998;18:263–269
  68. Gaudio E, Barbaro B, Alvaro D, et al. Administration of r-vegf-a prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am J Physiol Gastrointest Liver Physiol. 2006;291:G307–G317
  69. Gaudio E, Franchitto A, Pannarale L, et al. Cholangiocytes and blood supply. World J Gastroenterol. 2006;12:3546–3552
  70. Deltenre P, Valla DC. Ischemic cholangiopathy. Semin Liver Dis. 2008;28:235–246
  71. Kmiec Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001;161:1–151
  72. Roberts RA, Ganey PE, Ju C, et al. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci. 2007;96:2–15
  73. Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct. 2003;28:105–112
  74. Atzori L, Poli G, Perra A. Hepatic stellate cell: a star cell in the liver. Int J Biochem Cell Biol. 2009;41:1639–1642
  75. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–172
  76. Okanoue T, Mori T, Sakamoto S, et al. Role of sinusoidal endothelial cells in liver disease. J Gastroenterol Hepatol. 1995;10(Suppl. 1):S35–S37
  77. Lenzi R, Alpini G, Liu MH, et al. Von willebrand factor antigen is not an accurate marker of rat and guinea pig liver endothelial cells. Liver. 1990;10:372–379
  78. Li Z, Dranoff JA, Chan EP, et al. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology. 2007;46:1246–1256
  79. Vermijlen D, Luo D, Robaye B, et al. Pit cells (hepatic natural killer cells) of the rat induce apoptosis in colon carcinoma cells by the perforin/granzyme pathway. Hepatology. 1999;29:51–56
  80. Matsunaga Y, Terada T. Mast cell subpopulations in chronic inflammatory hepatobiliary diseases. Liver. 2000;20:152–156
  81. Nakamura A, Yamazaki K, Suzuki K, et al. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am J Gastroenterol. 1997;92:2245–2249
  82. Stoyanova II. Relevance of mast cells and hepatic lobule innervation to liver injury. Rom J Gastroenterol. 2004;13:203–209
  83. Alfter K, von Kugelgen I, Haenisch B, et al. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. 2009;29:181–186
  84. Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut. 1990;31:96–99
  85. Takeshita A, Shibayama Y. Role of mast cells in hepatic remodeling during cholestasis and its resolution: relevance to regulation of apoptosis. Exp Toxicol Pathol. 2005;56:273–280
  86. Crosignani A, Battezzati PM, Invernizzi P, et al. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol. 2008;14:3313–3327
  87. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3350–3359
  88. Abbas G, Lindor KD. Cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Cancer. 2009;40:19–25
  89. Tsuneyama K, Saito K, Ruebner BH, et al. Immunological similarities between primary sclerosing cholangitis and chronic sclerosing sialadenitis: report of the overlapping of these two autoimmune diseases. Dig Dis Sci. 2000;45:366–372
  90. Ishii M, Iwai M, Harada Y, et al. A role of mast cells for hepatic fibrosis in primary sclerosing cholangitis. Hepatol Res. 2005;31:127–131
  91. He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol. 2004;10:309–318
  92. Middel P, Reich K, Polzien F, et al. Interleukin 16 expression and phenotype of interleukin 16 producing cells in crohn's disease. Gut. 2001;49:795–803
  93. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 2004;1:98–105
  94. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol. 2009;25:223–229
  95. Xu GF, Wang XY, Ge GL, et al. Dynamic changes of capillarization and peri-sinusoid fibrosis in alcoholic liver diseases. World J Gastroenterol. 2004;10:238–243
  96. Neubauer K, Saile B, Ramadori G. Liver fibrosis and altered matrix synthesis. Can J Gastroenterol. 2001;15:187–193
  97. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005;115:56–65
  98. Mori T, Okanoue T, Sawa Y, et al. Defenestration of the sinusoidal endothelial cell in a rat model of cirrhosis. Hepatology. 1993;17:891–897
  99. Neubauer K, Kruger M, Quondamatteo F, et al. Transforming growth factor-beta1 stimulates the synthesis of basement membrane proteins laminin, collagen type iv and entactin in rat liver sinusoidal endothelial cells. J Hepatol. 1999;31:692–702
  100. Xu GF, Li PT, Wang XY, et al. Dynamic changes in the expression of matrix metalloproteinases and their inhibitors, timps, during hepatic fibrosis induced by alcohol in rats. World J Gastroenterol. 2004;10:3621–3627
  101. Gaca MD, Pickering JA, Arthur MJ, et al. Human and rat hepatic stellate cells produce stem cell factor: a possible mechanism for mast cell recruitment in liver fibrosis. J Hepatol. 1999;30:850–858
  102. Peng X, Wang B, Wang T, et al. Expression of basic fibroblast growth factor in rat liver fibrosis and hepatic stellate cells. J Huazhong Univ Sci Technol Med Sci. 2005;25:166–169222
  103. Napoli J, Prentice D, Niinami C, et al. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated rat model of cirrhosis. Hepatology. 1997;26:624–633
  104. Jeong DH, Lee GP, Jeong WI, et al. Alterations of mast cells and tgf-beta1 on the silymarin treatment for ccl(4)-induced hepatic fibrosis. World J Gastroenterol. 2005;11:1141–1148
  105. Komeda K, Jin D, Takai S, et al. Significance of chymase-dependent angiotensin ii formation in the progression of human liver fibrosis. Hepatol Res. 2008;38:501–510
  106. Fyhrquist F, Saijonmaa O. Renin–angiotensin system revisited. J Intern Med. 2008;264:224–236
  107. Kagami S, Border WA, Miller DE, et al. Angiotensin ii stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431–2437
  108. Takai S, Jin D, Sakaguchi M, et al. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-a zetidine-2-yloxy]-benzoic acid (bceab), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther. 2003;305:17–23
  109. Shimizu S, Satomura K, Aramaki T, et al. Hepatic chymase level in chronic hepatitis: co-localization of chymase with fibrosis. Hepatol Res. 2003;27:62–66
  110. Qyang Y, Senyei G. Regeneration of a heart cell. Yale J Biol Med. 2009;82:117–119
  111. Groot Kormelink T, Abudukelimu A, Redegeld FA. Mast cells as target in cancer therapy. Curr Pharm Des. 2009;15:1868–1878
  112. Della Rovere F, Granata A, Monaco M, et al. Phagocytosis of cancer cells by mast cells in breast cancer. Anticancer Res. 2009;29:3157–3161
  113. Ranieri G, Ammendola M, Patruno R, et al. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009;35:115–120
  114. Cervello M, Foderaa D, Florena AM, et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol. 2005;11:4638–4643
  115. Terada T, Matsunaga Y. Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol. 2000;33:961–966
  116. Lampiasi N, Azzolina A, Montalto G, et al. Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells. Exp Mol Med. 2007;39:284–294
  117. Fujikawa T, Shiraha H, Nakanishi Y, et al. Cimetidine inhibits epidermal growth factor-induced cell signaling. J Gastroenterol Hepatol. 2007;22:436–443
  118. Francis H, DeMorrow H, Venter J, et al. Evidence for a novel role for histamine regulation of cholangiocarcinoma growth by an autocrine mechanism. Gastroenterology. 2008;134:A58
  119. Francis H, Onori P, Gaudio E, et al. H3 histamine receptor-mediated activation of protein kinase c{alpha} inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res. 2009;[Epub ahead of print] PMID: 19825989
  120. Okazaki T, Hirota S, Xu ZD, et al. Increase of mast cells in the liver and lung may be associated with but not a cause of fibrosis: demonstration using mast cell-deficient ws/ws rats. Lab Invest. 1998;78:1431–1438

PII: S1590-8658(10)00087-3

doi: 10.1016/j.dld.2010.02.016

Digestive and Liver Disease
Volume 42, Issue 8 , Pages 529-536 , August 2010

Article Tools

* Image Usage & Resolution